Literature DB >> 24042161

Differential long-term effects of haloperidol and risperidone on the acquisition and performance of tasks of spatial working and short-term memory and sustained attention in rats.

Elizabeth J Hutchings1, Jennifer L Waller, Alvin V Terry.   

Abstract

A common feature of the neuropsychiatric disorders for which antipsychotic drugs are prescribed is cognitive dysfunction, yet the effects of long-term antipsychotic treatment on cognition are largely unknown. In the current study, we evaluated the effects of long-term oral treatment with the first-generation antipsychotic haloperidol (1.0 and 2.0 mg/kg daily) and the second-generation antipsychotic risperidone (1.25 and 2.5 mg/kg daily) on the acquisition and performance of two radial-arm maze (RAM) tasks and a five-choice serial reaction-time task (5C-SRTT) in rats during days 15-60 and 84-320 days of treatment, respectively. In the RAM, neither antipsychotic significantly affected the acquisition or performance of a spatial win shift or a delayed non-match-to-position task. Conversely, in the rats administered 5C-SRTT, haloperidol was associated with profound deficits in performance, and the subjects were not able to progress through all stages of task acquisition. Depending on the dose, risperidone was associated with a greater number of trials to meet specific performance criteria during task acquisition compared with vehicle-treated controls; however, most subjects were eventually able to achieve all levels of task acquisition. Both haloperidol and risperidone also increased the number of perseverative and time-out responses during certain stages of task acquisition, and the response and reward latencies were slightly higher than controls during several stages of the study. These results in rats suggest that while long-term treatment with haloperidol or risperidone may not significantly affect spatial working or short-term memory, both antipsychotics can (depending on dose) impair sustained attention, decrease psychomotor speed, increase compulsive-type behaviors, and impair cognitive flexibility.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24042161      PMCID: PMC3836316          DOI: 10.1124/jpet.113.209031

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

1.  A continuous performance test of brain damage.

Authors:  L H BECK; E D BRANSOME; A F MIRSKY; H E ROSVOLD; I SARASON
Journal:  J Consult Psychol       Date:  1956-10

Review 2.  Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.

Authors:  S Miyamoto; G E Duncan; C E Marx; J A Lieberman
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

Review 3.  Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies.

Authors:  Terry E Goldberg; Richard S E Keefe; Robert S Goldman; Delbert G Robinson; Philip D Harvey
Journal:  Neuropsychopharmacology       Date:  2010-01-20       Impact factor: 7.853

4.  Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats.

Authors:  A V Terry; S E Warner; L Vandenhuerk; A Pillai; S P Mahadik; G Zhang; M G Bartlett
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

Review 5.  Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia.

Authors:  Nurith Amitai; Athina Markou
Journal:  Biol Psychiatry       Date:  2010-05-21       Impact factor: 13.382

Review 6.  Effect of second-generation antipsychotics on cognition: current issues and future challenges.

Authors:  S Kristian Hill; Jeffrey R Bishop; Donna Palumbo; John A Sweeney
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

7.  Chronic antipsychotic treatment: protracted decreases in phospho-TrkA levels in the rat hippocampus.

Authors:  Alvin V Terry; Debra A Gearhart; Anilkumar Pillai; Guodong Zhang; Michael G Bartlett
Journal:  Int J Neuropsychopharmacol       Date:  2010-01-11       Impact factor: 5.176

Review 8.  Impaired attention, genetics, and the pathophysiology of schizophrenia.

Authors:  B A Cornblatt; J G Keilp
Journal:  Schizophr Bull       Date:  1994       Impact factor: 9.306

9.  Protracted effects of chronic oral haloperidol and risperidone on nerve growth factor, cholinergic neurons, and spatial reference learning in rats.

Authors:  A V Terry; D A Gearhart; S Warner; E J Hohnadel; M-L Middlemore; G Zhang; M G Bartlett; S P Mahadik
Journal:  Neuroscience       Date:  2007-09-14       Impact factor: 3.590

10.  Effects of chronic haloperidol on reaction time and errors in a sustained attention task: partial reversal by anticholinergics and by amphetamine.

Authors:  B J Brockel; S C Fowler
Journal:  J Pharmacol Exp Ther       Date:  1995-12       Impact factor: 4.030

View more
  3 in total

1.  Divergent long-term consequences of chronic treatment with haloperidol, risperidone, and bromocriptine on traumatic brain injury-induced cognitive deficits.

Authors:  Thomas I Phelps; Corina O Bondi; Rashid H Ahmed; Yewande T Olugbade; Anthony E Kline
Journal:  J Neurotrauma       Date:  2015-01-08       Impact factor: 5.269

2.  Combining the Antipsychotic Drug Haloperidol and Environmental Enrichment after Traumatic Brain Injury Is a Double-Edged Sword.

Authors:  Kaitlin A Folweiler; Corina O Bondi; Elizabeth A Ogunsanya; Megan J LaPorte; Jacob B Leary; Hannah L Radabaugh; Christina M Monaco; Anthony E Kline
Journal:  J Neurotrauma       Date:  2016-04-20       Impact factor: 5.269

3.  Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss.

Authors:  W R Crum; F Danckaers; T Huysmans; M-C Cotel; S Natesan; M M Modo; J Sijbers; S C R Williams; S Kapur; A C Vernon
Journal:  Psychol Med       Date:  2016-08-12       Impact factor: 7.723

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.